Drug Profile
Research programme: small molecule therapeutics - Janssen Biotech/Nuevolution
Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Nuevolution
- Developer Janssen Biotech; Nuevolution
- Class Anti-infectives; Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Infections; Inflammation
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Cancer in Denmark
- 28 Nov 2019 No recent reports of development identified for research development in Infections in Denmark
- 28 Nov 2019 No recent reports of development identified for research development in Inflammation in Denmark